ISIN | LU0942225912 |
---|---|
Valor Number | 21612660 |
Bloomberg Global ID | |
Fund Name | Candriam Equities L Biotechnology R-Acc |
Fund Provider |
CANDRIAM
Serenity, Bloc - B, 19-21, route d'Arlon 8009 Strassen E-Mail: CH@Candriam.com Phone: + 352 2797-1 Web: https://www.candriam.com |
Fund Provider | CANDRIAM |
Representative in Switzerland |
CACEIS (Switzerland) SA Nyon Phone: +41 22 360 94 00 |
Distributor(s) | |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | The objective of the sub-fund is to use discretionary management to benefit from the performance of the market in global equities of companies from the biotechnology sector, and to outperform the benchmark. This sub-fund may be appropriate for investors who wish to achieve this objective over a long investment holding period and who are aware of, understand and are able to bear the specific risks of the sub-fund. |
Peculiarities |
Current Price * | 266.76 USD | 03.07.2025 |
---|---|---|
Previous Price * | 265.65 USD | 02.07.2025 |
52 Week High * | 307.14 USD | 08.11.2024 |
52 Week Low * | 226.85 USD | 08.04.2025 |
NAV * | 266.76 USD | 03.07.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 1,131,393,734 | |
Unit/Share Assets *** | 32,258,048 | |
Trading Information SIX |
YTD Performance | -1.54% |
31.12.2024 - 03.07.2025
31.12.2024 03.07.2025 |
---|---|---|
YTD Performance (in CHF) | -13.74% |
31.12.2024 - 03.07.2025
31.12.2024 03.07.2025 |
1 month | +2.66% |
03.06.2025 - 03.07.2025
03.06.2025 03.07.2025 |
3 months | +6.30% |
03.04.2025 - 03.07.2025
03.04.2025 03.07.2025 |
6 months | -2.61% |
03.01.2025 - 03.07.2025
03.01.2025 03.07.2025 |
1 year | -2.31% |
03.07.2024 - 03.07.2025
03.07.2024 03.07.2025 |
2 years | +10.59% |
03.07.2023 - 03.07.2025
03.07.2023 03.07.2025 |
3 years | +21.88% |
05.07.2022 - 03.07.2025
05.07.2022 03.07.2025 |
5 years | +14.69% |
06.07.2020 - 03.07.2025
06.07.2020 03.07.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Amgen Inc | 6.28% | |
---|---|---|
Gilead Sciences Inc | 6.12% | |
Alnylam Pharmaceuticals Inc | 5.87% | |
Vertex Pharmaceuticals Inc | 5.61% | |
Regeneron Pharmaceuticals Inc | 4.31% | |
Neurocrine Biosciences Inc | 2.85% | |
BeOne Medicines Ltd ADR | 2.79% | |
Insmed Inc | 2.66% | |
BioNTech SE ADR | 2.59% | |
Ascendis Pharma AS ADR | 2.48% | |
Last data update | 31.05.2025 |
TER *** | 1.09% |
---|---|
TER date *** | 31.12.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 0.90% |
Ongoing Charges *** | 1.11% |
SRRI ***
|
|
SRRI date *** | 30.06.2025 |